**Background**: The recently emerged Middle East syndrome coronavirus (MERS-CoV) can cause severe and fatal respiratory diseases in humans. Antibodies against MESR-CoV can be found in camels in the Middle East but also outside this regionThe high prevalence of circulating MERS-CoV neutralizing antibodies in dromedary camels from different geographic regions may indicate wide circulation of MERS-CoV in camels. The ongoing MERS-CoV outbreak in the Middle East and the lack of treatment options or licensed vaccines is of great concern. Vaccination of camels could potentially prevent the spread of this virus.

**Methods & Materials**: We vaccinated 4 dromedary camels twice with a 4 week interval with10^8^ PFU MVA-S via both nostrils and intramuscularly. Four control animals received non-recombinant MVA (n=2) or PBS (n=2). Three weeks post-boost, all animals were tested for presence specific antibody responses by MERS-CoV ELSA and virus neutralization assay (VNT). Next, all camels were challenged with a high dose of MERS-CoV and to study the pathological changes, two animals per groups were euthanized and necropsies were performed at day 4 and 14 pi. The antibody response, and pathology were analyses by MERS-CoV-S or MVA ELISAs, -VNTs, qRT-PCR, virus titration, immunohistochemistry (IHC) and *in situ* hybridization (ISH).

**Results**: All vaccinated animal developed detectable serum neutralizing MERS-CoV or MVA specific antibody titers 3 weeks post boost vaccination. No clinical signs were observed in MVA-S vaccinated animals but mild clinical sign and a runny nose were observed in control-vaccinated animals after virus challenge. Interestingly, significant reduction of infectious virus excreted and viral RNA transcripts in the vaccinated animals nose after MERS-CoV challenge was observed as compared with control animals, and these protection correlated with presence of neutralizing antibody to MERS-CoV. In addition, in the nose of MVA-S vaccinated animals at day 4 pi, a few MERS-CoV infected cells were detected by IHC and ISH as compared with control camels. Interestingly, sera from MVA-S vaccinated animals cross neutralized camelpox virus.

**Conclusion**: Our results demonstrate that vaccination of camels with MVA-S confers protects against MERS-CoV infection. In addition, induction of MVA specific antibody cross neutralize camelpox virus, suggesting that MVA-MERS-S can be used as a dual vaccine in dromedary camels.
